FluoroPharma Medical, Inc. (OTCQB: FPMI)

FluoroPharma Medical, Inc. (FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD).

Quick Links

Corporate Presentation

Company Information

FluoroPharma Medical, Inc.
8 Hillside Ave
Suite 108
Montclair, NJ 07042

Management Team

Thomas Tulip
CEO & President

Transfer Agent

Vstock Transfer, LLC
77 Spruce Street
Suite 201
Cedarhurst, New York 11516
(212) 828-8436

Auditors

Wolf & Company, P.C.
99 High Street
Boston, MA 02110
(617) 933-3368